These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34986552)

  • 1. Impact of somatic mutations on clinical and pathologic outcomes in borderline resectable and locally advanced pancreatic cancer treated with neoadjuvant chemotherapy and stereotactic body radiotherapy followed by surgical resection.
    Reddy AV; Hill CS; Sehgal S; Ding D; Hacker-Prietz A; He J; Zheng L; Herman JM; Meyer J; Narang AK
    Radiat Oncol J; 2021 Dec; 39(4):304-314. PubMed ID: 34986552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High neutrophil-to-lymphocyte ratio following stereotactic body radiation therapy is associated with poor clinical outcomes in patients with borderline resectable and locally advanced pancreatic cancer.
    Reddy AV; Hill CS; Sehgal S; He J; Zheng L; Herman JM; Meyer J; Narang AK
    J Gastrointest Oncol; 2022 Feb; 13(1):368-379. PubMed ID: 35284125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
    Gao S; Zhu X; Shi X; Cao K; Bian Y; Jiang H; Wang K; Guo S; Zhang H; Jin G
    Radiat Oncol; 2019 Mar; 14(1):52. PubMed ID: 30917842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.
    Wolfe AR; Prabhakar D; Yildiz VO; Cloyd JM; Dillhoff M; Abushahin L; Alexandra Diaz D; Miller ED; Chen W; Frankel WL; Noonan A; Williams TM
    Cancer Med; 2020 Jul; 9(13):4711-4723. PubMed ID: 32415696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.
    Mellon EA; Jin WH; Frakes JM; Centeno BA; Strom TJ; Springett GM; Malafa MP; Shridhar R; Hodul PJ; Hoffe SE
    Acta Oncol; 2017 Mar; 56(3):391-397. PubMed ID: 27885876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi-agent chemotherapy.
    Hill C; Sehgal S; Fu W; Hu C; Reddy A; Thompson E; Hacker-Prietz A; Le D; De Jesus-Acosta A; Lee V; Zheng L; Laheru DA; Burns W; Weiss M; Wolfgang C; He J; Herman JM; Meyer J; Narang A
    Cancer Med; 2022 Apr; 11(7):1659-1668. PubMed ID: 35142085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial.
    Bouchart C; Navez J; Borbath I; Geboes K; Vandamme T; Closset J; Moretti L; Demetter P; Paesmans M; Van Laethem JL
    BMC Cancer; 2023 Sep; 23(1):891. PubMed ID: 37735634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer.
    Rajagopalan MS; Heron DE; Wegner RE; Zeh HJ; Bahary N; Krasinskas AM; Lembersky B; Brand R; Moser AJ; Quinn AE; Burton SA
    Radiat Oncol; 2013 Oct; 8():254. PubMed ID: 24175982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
    Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
    Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity.
    Hill CS; Rosati LM; Hu C; Fu W; Sehgal S; Hacker-Prietz A; Wolfgang CL; Weiss MJ; Burkhart RA; Hruban RH; De Jesus-Acosta A; Le DT; Zheng L; Laheru DA; He J; Narang AK; Herman JM
    Ann Surg Oncol; 2022 Apr; 29(4):2456-2468. PubMed ID: 35129721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
    Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
    BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy.
    Reddy AV; Hill CS; Sehgal S; Zheng L; He J; Laheru DA; Jesus-Acosta A; Herman JM; Meyer J; Narang AK
    Radiat Oncol J; 2022 Jun; 40(2):111-119. PubMed ID: 35796114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-based split stereotactic body radiation therapy for borderline resectable and locally advanced pancreatic cancer: study protocol of a prospective, single-arm phase II trial.
    Zheng R; Wang C; Huang X; Lin Q; Huang D; Li XB; Huang H; Xu B
    BMJ Open; 2020 Nov; 10(11):e039900. PubMed ID: 33154057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.
    Ghaneh P; Palmer D; Cicconi S; Jackson R; Halloran CM; Rawcliffe C; Sripadam R; Mukherjee S; Soonawalla Z; Wadsley J; Al-Mukhtar A; Dickson E; Graham J; Jiao L; Wasan HS; Tait IS; Prachalias A; Ross P; Valle JW; O'Reilly DA; Al-Sarireh B; Gwynne S; Ahmed I; Connolly K; Yim KL; Cunningham D; Armstrong T; Archer C; Roberts K; Ma YT; Springfeld C; Tjaden C; Hackert T; Büchler MW; Neoptolemos JP;
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):157-168. PubMed ID: 36521500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review.
    Eshmuminov D; Aminjonov B; Palm RF; Malleo G; Schmocker RK; Abdallah R; Yoo C; Shaib WL; Schneider MA; Rangelova E; Choi YJ; Kim H; Rose JB; Patel S; Wilson GC; Maloney S; Timmermann L; Sahora K; Rössler F; Lopez-Lopez V; Boyer E; Maggino L; Malinka T; Park JY; Katz MHG; Prakash L; Ahmad SA; Helton S; Jang JY; Hoffe SE; Salvia R; Taieb J; He J; Clavien PA; Held U; Lehmann K
    Ann Surg Oncol; 2023 Jul; 30(7):4417-4428. PubMed ID: 37020094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreatic cancer.
    Zakem SJ; Mueller AC; Meguid C; Torphy RJ; Holt DE; Schefter T; Messersmith WA; McCarter MD; Del Chiaro M; Schulick RD; Goodman KA
    HPB (Oxford); 2021 Jul; 23(7):1072-1083. PubMed ID: 33277184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy.
    Wijetunga AR; Chua TC; Nahm CB; Pavlakis N; Clarke S; Chan DL; Diakos C; Maloney S; Ashrafi-Zadeh A; Kneebone A; Hruby G; Jamieson NB; Gill A; Mittal A; Samra JS
    Eur J Surg Oncol; 2021 Oct; 47(10):2543-2550. PubMed ID: 33952409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of neoadjuvant Folfirinox and Gemcitabine plus Nab-Paclitaxel for borderline resectable and locally advanced pancreatic cancer: a systematic review and meta-analysis.
    Dong LP; Liu YM; Lu WJ; Tang KZ
    Eur Rev Med Pharmacol Sci; 2022 Sep; 26(17):6316-6327. PubMed ID: 36111933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Timing of Surgery Following Stereotactic Body Radiation Therapy Impacts Local Control for Borderline Resectable or Locally Advanced Pancreatic Cancer.
    Lin T; Reddy A; Hill C; Sehgal S; He J; Zheng L; Herman J; Meyer J; Narang A
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer.
    Lu C; Zhu Y; Kong W; Yang J; Zhu L; Wang L; Tang M; Chen J; Li Q; He J; Li A; Qiu X; Gu Q; Chen D; Meng F; Liu B; Qiu Y; Du J
    Front Oncol; 2022; 12():879661. PubMed ID: 36059628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.